WO2012039474A1 - ピロロキノリンキノンのカルシウム塩 - Google Patents
ピロロキノリンキノンのカルシウム塩 Download PDFInfo
- Publication number
- WO2012039474A1 WO2012039474A1 PCT/JP2011/071697 JP2011071697W WO2012039474A1 WO 2012039474 A1 WO2012039474 A1 WO 2012039474A1 JP 2011071697 W JP2011071697 W JP 2011071697W WO 2012039474 A1 WO2012039474 A1 WO 2012039474A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- pyrroloquinoline quinone
- calcium salt
- salt
- pqq
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a method for producing a calcium salt of pyrroloquinoline quinone and a calcium salt of pyrroloquinoline quinone obtained by the production method.
- the invention also relates to the use of the calcium salt of pyrroloquinoline quinone.
- PQQ Pyrroloquinoline quinone
- Non-Patent Document 1 Pyrroloquinoline quinone
- PQQ Pyrroloquinoline quinone
- PQQ has been shown to promote cell proliferation, anti-cataract, liver disease preventive and therapeutic, wound healing, anti-allergy, reverse transcriptase inhibitor and glyoxalase I inhibitor-antitumor, Many physiological activities such as fiber regeneration have been revealed.
- higher crystallinity is known to provide chemical stability and longer shelf life, resulting in less need to stabilize the agent and having a longer shelf life, and It may be provided in a relatively simple packaging form.
- PQQ is obtained by subjecting PQQ obtained by an organic chemical synthesis method (Non-patent Document 2) or fermentation method (Patent Document 1) to chromatography, concentrating the PQQ section in the effluent, and adding an organic solvent. It can be obtained by crystallization by crystallization (Patent Document 2) and drying.
- the alkali metal salt of PQQ is made by adding alcohol from an aqueous solution and precipitating it with reduced solubility, its crystallinity is not high. Further, since this method uses an organic solvent that is expensive and flammable and increases the cost of waste liquid treatment, there is a need for a method that does not use this.
- Non-Patent Document 2 disodium salt crystals are obtained, but this method has low productivity and is not industrially useful. Furthermore, calcium ion is important as a nutritional component, and it is desired to be taken at the same time as pyrroloquinoline. However, there has been no report on a specific method for producing a calcium salt of PQQ.
- Patent Document 2 mentions an alkaline earth metal salt as well as an alkali metal salt, but there is no example, and since it is a method of crystallizing using an organic solvent, in order to handle flammable substances. Equipment and drainage facilities become expensive. Alkali metal salts are water-soluble and easily react with amines, carbonyls, and reducing compounds, and particularly easily react in an environment with dissolved water. Therefore, in order to improve stability, low water solubility is required. It is desired that PQQ be easily absorbed when administered as food or medicine.
- PQQ and its salts are often obtained as red or a darker color. These colors are known as colors specific to PQQ, but when they are mixed with foods or medicines, the colors appear strongly, and the intended color may not be achieved. In particular, in foods where palatability is important, this color may be an obstacle to designing the target color. Therefore, the color of PQQ is desired to be closer to white.
- the color of PQQ can appear white by mixing with a coating or other ingredients. However, the mixing of non-essential components has the disadvantage that the degree of freedom in designing the ingredients of food and medicine is lowered. When coating or the like is performed, the same function as the original PQQ or the return to the PQQ is required.
- the present inventors produce a calcium salt of pyrroloquinoline quinone by precipitating crystals from a solution obtained by mixing an aqueous solution of pyrroloquinoline quinone or its alkali metal salt and an aqueous solution of a calcium ion source.
- the obtained calcium salt was found to have high crystallinity and low water solubility.
- the inventors have also found that a white calcium salt can be obtained under certain conditions.
- the present invention is based on these findings.
- An object of the present invention is to provide a method of producing a PQQ salt that has high crystallinity and low water solubility and can easily release PQQ without using a large amount of an organic solvent. To do. Specifically, it aims at providing the manufacturing method of the calcium salt of PQQ, and its highly purified crystal
- the calcium salt of pyrroloquinoline quinone according to (1) obtained by precipitating from a mixture obtained by mixing pyrroloquinoline quinone or an alkali metal salt thereof and a calcium ion source in a solution.
- a pyrroloquinoline quinone-containing composition comprising: (10) The chelating substance is at least one selected from the group consisting of phosphoric acid, pyrophosphoric acid, nucleic acid, phytic acid, tartaric acid, succinic acid, citric acid, EDTA, hexametaphosphoric acid and polyphosphoric acid, (9) A composition according to 1.
- a method for producing a calcium salt of pyrroloquinoline quinone comprising obtaining a precipitate from a mixture obtained by mixing pyrroloquinoline quinone or an alkali metal salt thereof and a calcium ion source in a solution.
- the present invention is advantageous in that a stable PQQ calcium salt having low water solubility and high crystallinity can be produced with high purity by an industrially useful method without using an organic solvent. Further, the obtained calcium salt of PQQ can be dissolved at the time of use, and it is advantageous in that it has high absorbability. According to the present invention, it is also advantageous in that a calcium salt of PQQ that is white or nearly white (pale red) can be produced.
- FIG. 1 is a graph showing the result of powder X-ray diffraction in Example 1.
- FIG. 2 is a graph showing the result of powder X-ray diffraction in Example 2.
- FIG. 3 is a graph showing the result of powder X-ray diffraction in Example 14.
- FIG. 4 shows the results of 1 H-NMR spectrum.
- FIG. 5 shows the results of 13 C-NMR spectrum.
- FIG. 6 is a diagram showing the XPS measurement results.
- a pyrroloquinoline quinone calcium salt can be produced by mixing pyrroloquinoline quinone or an alkali metal salt thereof and a calcium ion source in a solution.
- the pyrroloquinoline quinone used in the present invention has a structure represented by the following formula (1).
- an alkali metal salt of pyrroloquinoline quinone means an alkali metal salt of a compound represented by the formula (1).
- a calcium salt of pyrroloquinoline quinone means a calcium salt of a compound represented by the formula (1).
- a water addition product of a calcium salt of pyrroloquinoline quinone is also included in the calcium salt of pyrroloquinoline quinone.
- a crystal of a calcium salt of pyrroloquinoline quinone means a crystal of a calcium salt of a compound represented by the formula (1), and in a state where pyrroloquinoline quinone molecules are regularly aligned in a solid state. In general, it is in a highly pure and highly stable state. Whether or not the calcium salt of pyrroloquinoline quinone is in the form of crystals can be confirmed by detecting a peak by powder X-ray diffraction.
- Measurement of the diffraction angle 2 ⁇ by powder X-ray diffraction can be performed, for example, under the following measurement conditions.
- Measurement condition Apparatus: RINT2500 manufactured by Rigaku Corporation
- X-ray Cu / tube voltage 40 kV / tube current 100 mA
- it can also be observed with a general powder X-ray diffractometer equipped with a monochromator.
- Examples of the alkali metal salt of pyrroloquinoline quinone used in the present invention include salts of sodium, potassium, lithium, cesium, rubidium and the like. Sodium salts and potassium salts are preferable, and sodium salts that are easy to obtain are particularly preferable. These may be used alone or in combination.
- the substitution number of the salt in the alkali metal salt of pyrroloquinoline quinone is 1 to 3, and any of a monoalkali metal salt, a dialkali metal salt, and a trialkali metal salt is preferable, but a dialkali metal salt is preferable.
- a disodium salt is particularly preferable.
- alkali metal salts of PQQ used in the present invention can also be obtained. It can also be produced by an organic chemical synthesis method, a fermentation method, or the like.
- the salt of PQQ used for the raw material may be crystalline or amorphous. Further, impurities may be included.
- the pyrroloquinoline quinone or its alkali metal salt used in the present invention can be used as a solution of pyrroloquinoline quinone or its alkali metal salt.
- the solvent used is not particularly limited as long as the reaction proceeds, and pyrroloquinoline quinone or an alkali metal salt thereof is dissolved in a solvent such as water, alcohol, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, or the like. can do.
- a solvent can be used individually or in mixture of 2 or more types.
- the solvent used is preferably water (aqueous solution).
- the solution of pyrroloquinoline quinone or an alkali metal salt thereof is, for example, preferably 0.1 to 100 g / L, more preferably 1 to 20 g / L.
- the pH of the pyrroloquinoline quinone or alkali metal salt solution thereof is preferably finally 1 to 12, more preferably 2 to 9, and more preferably 2 to 7.
- the number of calcium substitutions can be controlled by adjusting and selecting this pH. 1 calcium salt per PQQ1 by adjusting the pH from 2 to 4 (preferably 2.5 to 4), more (eg greater than 4 and less than 7 and preferably 4.5 to 7)
- 1.5 calcium salts can be obtained for PQQ1.
- the pH is less than 4 (for example, 1.5 to less than 4, preferably 1.5 to 3.5, more preferably 2 to 2). 3) can be adjusted.
- acid or alkali can be added to the solution of PQQ or its alkali metal salt to change the pH.
- the acid or alkali used to change the pH is preferably a substance having low reactivity with pyrroloquinoline quinone or calcium, and this kind is not particularly limited.
- Either inorganic or organic can be used.
- the inorganic acid include hydrochloric acid, hydrogen bromide, hydrogen iodide, perchloric acid, sulfuric acid, phosphoric acid, and nitric acid.
- organic acid include acetic acid, formic acid, oxalic acid, lactic acid, and citric acid. Is mentioned.
- Examples of the inorganic alkali include sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, calcium bicarbonate, and calcium oxide.
- Examples of the organic alkali include tetramethylammonium hydroxide. Quaternary ammonium hydroxide, amine, etc. are mentioned. These can be used alone or in combination.
- the temperature of the operation for adjusting the pH of the present invention is not particularly limited, but it is generally easy to handle from -20 ° C to 140 ° C. Preferably, it is 0 to 140 ° C, more preferably 20 to 90 ° C. It is easier to handle by heating to increase the solubility of the alkali metal salt of pyrroloquinoline quinone. However, as will be described later, when white PQQ calcium salt is produced, it is preferably 38 ° C. or lower, more preferably ⁇ 20 to 30 ° C. The lower the temperature, the more easily the precursor that changes white can be provided.
- the calcium ion source used in the present invention may be any substance that can supply calcium ions, such as calcium chloride, calcium bromide, calcium iodide, calcium carbonate, calcium bicarbonate, calcium hydroxide, acetic acid. Examples include calcium compounds such as calcium, calcium oxide, calcium lactate, and calcium phosphate.
- the calcium ion source used in the present invention is preferably a substance having a solubility at 25 ° C. of 0.01 g / L or more, more preferably 1 g / L or more. From the viewpoint of solubility, calcium carbonate, calcium chloride and calcium hydroxide are preferred, and calcium chloride is more preferred.
- the calcium ion source used in the present invention can be used as it is (powder) or as a solution, but is preferably used as a solution.
- the solvent used is not particularly limited as long as the reaction proceeds, and the calcium ion source can be used by dissolving in a solvent such as water, alcohol, dimethyl sulfoxide, dimethylformamide, dimethylacetamide and the like.
- a solvent can be used individually or in mixture of 2 or more types.
- the solvent used is preferably water (aqueous solution).
- the weight ratio of pyrroloquinoline quinone or its alkali metal salt to calcium ion source is 1: 0.1-100, preferably 1: 0.1-20, more preferably 1: 0.1-10, Preferably, it can be 1: 0.3-5.
- a calcium body can be produced by reacting and precipitating pyrroloquinoline quinone or its alkali metal salt with calcium ions.
- pyrroloquinoline quinone or its alkali metal salt and a calcium ion source are mixed in a solution to form a calcium salt, which can be obtained by precipitating it.
- the process of “mixing pyrroloquinoline quinone or an alkali metal salt thereof and a calcium ion source in a solution” may be performed as long as pyrroloquinoline quinone or an alkali metal salt thereof and calcium ion can be reacted in a solvent.
- it can be performed by mixing a solution of pyrroloquinoline quinone or an alkali metal salt thereof with a calcium ion source solution, or by adding a calcium ion source to a solution of pyrroloquinoline quinone or an alkali metal salt thereof. You can also.
- mixing can be performed by adding one mixing object to the other mixing object, or by adding the mixing object to another container.
- an additive can be added to an addition target at a time or can be gradually added.
- the reaction pH is not particularly limited, but can be, for example, 1 to 12, preferably 2 to 9, and more preferably 2 to 7.
- the reaction pH can be less than 4, preferably from 1.5 to less than 4, more preferably from 1.5 to 3.5, and even more preferably from 2 to 3.
- the reaction temperature is not particularly limited, but can be, for example, ⁇ 20 to 140 ° C., and preferably 0 to 120 ° C.
- the reaction time is not particularly limited, but can be, for example, 5 minutes to 1 week.
- the ratio of pyrroloquinoline quinone ion to calcium ion is preferably 1: 0.5 to 1.5. More preferably, it is 1: 1 to 1.5.
- the carboxylic acid of PQQ is a salt formed with calcium.
- a substance having high crystallinity often has high stability, and the present invention is also preferably crystalline.
- PQQ or its alkali metal salt is dissolved in water. The reaction can proceed even if dissolution is not complete.
- an acid or alkali solution may be added for adjustment.
- the concentration of PQQ or its alkali metal salt is preferably 0.1 to 100 g / L, more preferably 1 to 20 g / L.
- the temperature is from 0 to 140 ° C., and it is good to use. In terms of solubility, high temperatures are easy to dissolve, so setting it to 50 ° C. or higher increases productivity.
- Calcium salt can be precipitated by adding calcium chloride here. Calcium can be added in the form of an aqueous solution or powder.
- the mixing time is not particularly limited, but it can be performed in 5 minutes to 1 week. If the scale is small, it takes a short time, but if it is large, it takes a long time.
- the PQQ calcium salt can be obtained as white.
- the white PQQ calcium salt of the present invention can be formed through the PQQ calcium salt (red) obtained as described above.
- the white PQQ calcium salt of the present invention is obtained by depositing a pyrroloquinoline quinone or its alkali metal salt and a calcium ion source in a solution (precipitate), that is, red PQQ calcium salt. It can be obtained by placing for a certain time at a predetermined pH in an environment where water exists.
- red PQQ calcium salt contained in a mixture of pyrroloquinoline quinone or an alkali metal salt thereof and a calcium ion source can be brought into contact with water.
- the red PQQ calcium salt can be present in an aqueous solution, or can be present in a mixed solution of water and an organic solvent. It is preferred that the red PQQ calcium salt be present in the aqueous solution.
- the pH of the mixture obtained by mixing pyrroloquinoline quinone or its alkali metal salt and a calcium ion source in a solution can be adjusted to be less than 4, preferably 1.5 or more and less than 4, More preferably, it can be 1.5 to 3.5, and more preferably 2 to 3.
- the pH of the mixture obtained by mixing pyrroloquinoline quinone or its alkali metal salt and a calcium ion source in a solution is less than 4, it can be used as it is without special adjustment.
- acid and alkali can be added to the mixture to change pH.
- Acids and alkalis are used to change the pH, but this type is not particularly limited.
- Either inorganic or organic can be used.
- the inorganic acid include hydrochloric acid, hydrogen bromide, hydrogen iodide, perchloric acid, sulfuric acid, phosphoric acid, and nitric acid.
- the organic acid include acetic acid, formic acid, oxalic acid, lactic acid, and citric acid. Is mentioned.
- examples of the inorganic alkali include sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, calcium bicarbonate, and calcium oxide.
- the organic alkali include tetramethylammonium hydroxide. Quaternary ammonium hydroxide, amine, etc. are mentioned. These can be used alone or in combination.
- the time for which a mixture obtained by mixing pyrroloquinoline quinone or its alkali metal salt and a calcium ion source in a solution in an environment where water is present can be 2 hours or more. Preferably, it is 24 hours or more, more preferably 48 hours or more, and still more preferably 72 hours or more.
- the mixture obtained by mixing pyrroloquinoline quinone or its alkali metal salt and a calcium ion source in a solution may be stirred.
- Stirring can be carried out by subjecting to magnetic stirring, mechanical stirring, manual stirring, shaking stirring, or the like.
- the temperature of the mixture obtained by mixing pyrroloquinoline quinone or its alkali metal salt and a calcium ion source in a solution can be carried out at ⁇ 20 to 120 ° C., more preferably 0 to 80 ° C.
- the reaction that changes white is faster when the reaction temperature is higher.
- a white pyrroloquinoline quinone calcium salt for example, the following steps can be carried out: (I) mixing an aqueous solution of pyrroloquinoline quinone or an alkali metal salt thereof with an aqueous solution of a calcium ion source; (Ii) obtaining a precipitate from the mixture obtained in step (i); and (iii) placing the mixture containing the precipitate obtained in step (ii) at a pH of less than 4 for 2 hours or more.
- the PQQ calcium salt (white) of the present invention produced through the above steps preferably has a ratio of pyrroloquinoline quinone ion to calcium ion of 1: 0.5 to 1.5. More preferably, it is 1: 1 to 1.5.
- the precipitated solid is separated from the liquid by filtration or centrifugation. This may be washed with water and further washed with an organic solvent such as ethanol if necessary.
- the obtained solid can be dehydrated by air drying and drying under reduced pressure.
- the production method of the present invention is a method in which a calcium salt can be produced by using water as a solvent without using an organic solvent.
- White PQQ calcium salt and red PQQ calcium salt may coexist, but can be separated by centrifugation.
- White salts can be obtained as crystals or amorphous.
- the calcium salt of pyrroloquinoline quinone of the present invention can be obtained in the form of crystals.
- a pyrroloquinoline quinone calcium salt crystal in which the ratio of pyrroloquinoline quinone ion to calcium ion is 1: 0.5 to 1.5, preferably 1: 1 to 1.5.
- the calcium salt of PQQ of the present invention has at least 7.7 °, 10.6 °, 19.1 °, 26.4 °, 38.6 ° as a 2 ⁇ peak using the above Cu K ⁇ radiation (whichever Can also be obtained as crystals of pyrroloquinoline quinone calcium exhibiting ⁇ 0.4 °.
- crystals of pyrroloquinoline quinone calcium exhibiting at least 9.8 °, 15.3 °, 17.1 °, 19.7 °, 26.3 °, 28.3 ° (all ⁇ 0.4 °) Can be obtained as The calcium salt of PQQ is red.
- the crystal of the present invention may be a single crystal or a mixture of these crystals.
- the measurement error can be ⁇ 0.4 °, preferably ⁇ 0.2 °, more preferably ⁇ 0.1 °.
- the crystal form defined in the present invention includes measurement errors, it is only necessary to have a reasonable identity regarding the angle of the peak.
- the calcium salt of PQQ of the present invention is hardly soluble. In order to easily dissolve the calcium salt of this hardly soluble PQQ, it can be easily carried out by reacting with a chelating substance and removing calcium. Therefore, a composition with a chelating substance is effective for controlling liberation. Any chelating substance may be used as long as it is effective against calcium. Examples of chelating substances that can be eaten include phosphoric acid (sodium hydrogen phosphate, potassium hydrogen phosphate, etc.), pyrophosphoric acid, Examples thereof include nucleic acids (such as DNA sodium), phytic acid, tartaric acid, succinic acid, citric acid, EDTA, hexametaphosphoric acid, polyphosphoric acid and the like and salts thereof.
- phosphoric acid sodium hydrogen phosphate, potassium hydrogen phosphate, etc.
- pyrophosphoric acid examples thereof include nucleic acids (such as DNA sodium), phytic acid, tartaric acid, succinic acid, citric acid, EDTA,
- the sparingly soluble calcium salt can be changed to water-soluble by exchanging the cation of the chelate substance by the reaction of the chelate substance.
- the calcium salt of poorly soluble PQQ When the calcium salt of poorly soluble PQQ is administered as it is to a cell or a living body, a substance that reacts with a large amount of calcium exists in the living body, so that it can be released and work.
- the size of the hardly soluble crystal is 1 ⁇ m or less which is suitable for cells to take up the substance, there is a possibility that it is promoted rather than being dissolved. This is thought to depend on a cellular uptake mechanism called endocytosis.
- the calcium salt of PQQ of the present invention can release calcium ions simultaneously with dissolution.
- the calcium salt of PQQ can easily release calcium ions in the presence of an organic solvent, particularly dimethyl sulfoxide, dimethylformamide, dimethylacetamide and the like.
- the crystal of PQQ calcium salt of the present invention can be used as an active ingredient of a pharmaceutical or functional food. That is, according to this invention, the pharmaceutical or foodstuff which comprises the crystal
- solid preparations such as tablets, capsules, granules, etc.
- sugars such as lactose, sucrose and mannitol, kaolin, talc, magnesium stearate etc. as lubricants, starch, sodium alginate as disintegrants
- binder examples include polyvinyl alcohol, cellulose, and gelatin
- surfactant include fatty acid esters
- plasticizer include glycerin and the like, but are not limited thereto. You may add a dissolution accelerator, a filler, etc. as needed.
- the crystal of PQQ calcium salt can be used alone or in combination with other materials.
- Materials that can be combined include vitamins such as vitamin B group, vitamin C and vitamin E, amino acids, astaxanthin, carotenoids such as ⁇ -carotene and ⁇ -carotene, ⁇ 3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid, Although omega-6 fatty acids, such as arachidonic acid, are illustrated, it is not limited to these.
- the calcium salt of pyrroloquinoline quinone thus obtained has a ratio of pyrroloquinoline quinone to calcium ions of about 1: 1.
- the calcium salt of pyrroloquinoline quinone thus obtained has a ratio of pyrroloquinoline quinone to calcium ions of about 1: 1.5.
- step (I) mixing an aqueous solution of pyrroloquinoline quinone of pH 2-7 or an alkali metal salt thereof with an aqueous solution of a calcium ion source; (Ii) obtaining a precipitate from the mixture obtained in step (i); and (iii) placing the mixture containing the precipitate obtained in step (ii) at pH 1.5 to 3.5 for at least 24 hours.
- a method for producing a calcium salt of pyrroloquinoline quinone and a calcium salt (crystal) of pyrroloquinoline quinone obtained by the production method are provided.
- the calcium salt of pyrroloquinoline quinone thus obtained is white.
- a method for producing a calcium salt of pyrroloquinoline quinone and a calcium salt (crystal) of pyrroloquinoline quinone obtained by the production method are provided.
- the calcium salt of pyrroloquinoline quinone thus obtained is white.
- the chelating substance is at least one selected from the group consisting of phosphoric acid, pyrophosphoric acid, nucleic acid, phytic acid, tartaric acid, succinic acid, citric acid, EDTA, hexametaphosphoric acid and polyphosphoric acid. 4] The composition described in the above. [6] A method for producing a calcium salt of pyrroloquinoline quinone, comprising reacting an alkali metal salt of pyrroloquinoline quinone with a calcium compound.
- Test Example 1 Culture medium obtained by culturing hyphomicrobium methylobolum DSM1869 based on Example 1 of raw material synthesis patent No. 2692167, centrifuging to remove cells and culture containing PQQ A supernatant was obtained.
- This strain can be obtained from DSM (Deutsche Sammlung von Mikroorganismen (German Collection of Microorganisms and Cell Cultures)).
- the aqueous solution of PQQ having a pH of 7.5 obtained by eluting with an aqueous NaCl solution was further cooled by adding NaCl to a concentration of 60 g / L to obtain a solid.
- the PQQ purity by UV absorption in the graph was 99.0% or more, and this solid was dissolved in ion-exchanged water to prepare 800 g of a solution containing PQQ 10 g / L. 200 mL of ethanol was added at this time, and a red solid precipitated, which was stirred at room temperature for 5 hours and then allowed to stand at 5 ° C. for 24 hours to precipitate a solid.
- the solid was collected by continuous centrifugation and dried under reduced pressure at 50 ° C.
- the powder X-ray diffraction spectrum of the obtained solid was measured, and the obtained solid (PQQ disodium salt) had a peak at the low angle side. In addition to the above, no peak was observed and the crystallinity was low.
- Example 1 PQQ crystallization (pH 6.4) 1 g of PQQ disodium salt obtained in Test Example 1 was added to 100 g of water and adjusted to pH 6.4 with NaOH. A solution prepared by dissolving 1 g of calcium chloride in 40 ml of water was added and stirred overnight, and then the precipitated solid was filtered and washed with water and ethanol. This was performed overnight at 50 ° C. under reduced pressure. A weight of 1.18 g of dark red crystals was obtained. The water content was 23%. As a result of analysis using ICP analysis, it was contained in a ratio of Ca 1.5 mol with respect to PQQ1, and Na content was 0 and no sodium was contained.
- the result of the powder X-ray diffraction of the obtained calcium body is shown in FIG. It was a crystalline PQQ calcium salt having peaks at 7.7 °, 10.6 °, 19.1 °, 26.4 °, and 38.6 °. This solid was a crystalline material with low water solubility.
- Example 2 PQQ crystallization (pH 3.5) 3 g of PQQ disodium salt was dissolved in 800 g of water. The pH at this time was 3.5. A solution prepared by dissolving 6 g of calcium chloride in 100 ml of water was added, and after stirring for 2 days, the precipitated solid was filtered and washed with water and ethanol. This was dried overnight under reduced pressure at 70 ° C. to obtain 3.29 g of a red solid. The water content was 11%. As a result of analysis using ICP analysis, it was contained at a ratio of Ca 1 mol to PQQ1, and Na content was 0 and sodium was not contained. The powder X-ray diffraction of the obtained calcium salt is shown in FIG. It was a crystalline PQQ calcium salt having peaks at 9.8 °, 15.3, 17.1, 19.7 °, 26.3 °, and 28.3 °. This solid was a crystalline material with low water solubility.
- Examples 1-1 and 2-1, Comparative Example 1 Absorption test using cells PQQ has an effect of increasing proliferation of cultured animal cells and an effect of suppressing cell proliferation when the concentration is high. This was used to test how cell absorption changes.
- Chinese hamster ovary cells (CHO-DHFR ⁇ , manufactured by Dainippon Sumitomo Pharma Co., Ltd.) were cultured in ⁇ -MEM + 10% fetal bovine serum medium at 5% CO 2 and 37 ° C. Using a 96-well plate made by Iwaki, it was added together with 100 ⁇ l of medium so that 6000 cells would be in one hole and cultured overnight. The culture solution was removed and a medium having a predetermined test concentration was added.
- test samples used were the crystalline PQQ calcium salt of Examples 1 and 2 and the PQQ disodium salt of Test Example 1 which were diluted with a medium and tested. Each sample was run twice and averaged.
- the test concentration was 150 ⁇ g / ML with the upper limit being changed to 1 ⁇ 2, and 2.3 ⁇ g / ML being the lower limit.
- the concentration (about 5%) at which the number of cells due to PQQ is the largest compared with no addition is described as the optimum growth concentration.
- the amount of addition in which the total number of cells is reduced by about 10% compared to the case of no addition is described as the growth-reducing concentration.
- Table 1 The results are shown in Table 1 below.
- the effective concentration for growth was about 16 to 1/32 compared to PQQ disodium salt, indicating that the absorbability was improved.
- the growth-reducing concentration is halved, indicating that the absorbability is improved.
- the absorbability was improved, and it was shown that the cell permeability was improved by the calcium salt.
- it is a poorly soluble salt the influence on a cell has appeared and it was shown that it is a form which can be utilized biologically.
- Examples 3-10, 1-2, 2-2 Dissolution test The change in solubility of insoluble salt by adding a chelating substance was measured.
- the chelating substance was mixed with the crystalline PQQ calcium salt obtained in Examples 1 and 2 and added to 1 ml of water, allowed to stand at room temperature for 4 hours, and then the liquid from which insoluble components were removed by centrifugation was removed from the absorption at 450 nm by the PQQ The amount of dissolution was measured.
- the results are shown in Table 2.
- the solubility of the calcium salt alone is very low.
- the solubility can be increased by combining a chelating substance with this insoluble salt.
- the solubility can be controlled by changing what is mixed, and can be changed according to the application.
- Example 11 PQQ crystallization (pH 4.8) The experiment was conducted in the same manner as in Example 1. However, the aqueous solution of PQQ disodium salt was adjusted to pH 4.8. The recovered amount and the like were the same as in Example 1, and the analysis result of the powder X-ray diffraction also had the same crystal structure as in Example 1. It was a salt with a ratio of Ca 1.5 mol to PQQ1.
- Example 13 PQQ crystallization (pH 6.6) 0.54 g of pyrroloquinoline quinone potassium salt was dissolved in 300 ml of water to adjust the pH to 6.6. The mixture was mixed with 20 ml of an aqueous solution containing 1.4 g of calcium chloride and stirred overnight. After filtration, washing with water and ethanol and drying under reduced pressure, 0.42 g of a solid was obtained. Powder X-ray diffraction of the obtained substance gave the same peak as in Example 1, and a calcium salt with a ratio of Ca 1.5 mol to PQQ1 could be produced.
- Example 14 Production of White Crystalline PQQ Calcium Salt
- the PQQ disodium salt obtained in Test Example 1 was dissolved in water to prepare a 2 g / L aqueous solution.
- 2 ml of 2N hydrochloric acid was added to 400 ml of this aqueous solution. It was mixed with 170 ml of an aqueous solution of calcium chloride (2 g / L) at a temperature of 10 ° C.
- the pH at the time of mixing was 2.3.
- After 30 minutes at 10 ° C. the mixture was stirred at 40 ° C. for 3 days. This was filtered and washed with 50 ml of water to give a white solid. Vacuum drying was performed overnight to obtain 0.76 g of solid.
- the powder X-ray diffraction results are shown in FIG. It was a crystalline white substance having peaks at 8.8 °, 17.5 °, 25.4 °, 28.1 °, 30.5 °, and 33.9 °.
- Example 15 Reaction at 10 ° C
- the PQQ disodium salt obtained in Test Example 1 was dissolved in water to prepare a 2 g / L aqueous solution.
- 2 ml of 2N hydrochloric acid was added to 400 ml of this aqueous solution. It was mixed with 170 ml of an aqueous solution of calcium chloride (2 g / L) at a temperature of 10 ° C.
- the pH at the time of mixing was 2.3. I left at 10 ° C for 3 days. This was filtered and washed with 50 ml of water to give a white solid. Drying under reduced pressure overnight gave 0.78 g of solid.
- the powder X-ray diffraction result was the same as in Example 14.
- Example 16 Reaction at pH 2.6
- the PQQ disodium salt obtained in Test Example 1 was dissolved in water to prepare a 2 g / L aqueous solution.
- 0.6 ml of 2N hydrochloric acid was added to 250 ml of this aqueous solution.
- 120 ml of an aqueous solution of calcium chloride (2 g / L) was mixed at room temperature (about 20 ° C.).
- the pH at the time of mixing was 2.6.
- the mixture was stirred at 40 ° C. for 6 days. This was filtered and washed with 10 ml of ethanol to obtain a white solid. Drying under reduced pressure overnight gave 0.50 g of solid.
- the powder X-ray diffraction result was the same as in Example 14.
- Example 17 Synthesis of white crystal precursor (red solid) An experiment was conducted in the same manner as in Example 15 except that the mixture was mixed at 10 ° C and filtered in 30 minutes. As a result, a red solid was obtained. Vacuum drying was performed overnight to obtain 0.79 g of a red solid.
- Example 18 pH adjustment with acetic acid PQQ disodium salt obtained in Test Example 1 was dissolved in water to prepare a 2 g / L aqueous solution. To 250 ml of this aqueous solution, 4.19 g of acetic acid was added. The mixture was mixed with 120 ml of an aqueous solution of calcium chloride (2 g / L) at room temperature. The pH at the time of mixing was 2.8. The mixture was stirred at 40 ° C. for 6 days, filtered, and washed with 10 ml of ethanol to obtain a white solid. Vacuum drying was performed overnight to obtain 0.51 g of a white solid.
- Example 19 Separation of white solid and red solid PQQ disodium salt obtained in Test Example 1 was dissolved in water to prepare a 2 g / L aqueous solution. 2 ml of 2N hydrochloric acid was added to 400 ml of this aqueous solution. It was mixed with 170 ml of an aqueous solution of calcium chloride (2 g / L) at room temperature. The pH at the time of mixing was 2.3. After 5 minutes, the temperature was raised to 70 ° C. and left for 1 day. Red and white solids were formed. This was divided into 50 ml centrifuge tubes, placed in a centrifuge HITACHI himac CF7D2, and subjected to 2000 rpm for 30 minutes. The bottom of the container was red and white was the upper layer and settled. A white solid and a red solid could be separated by a specific gravity difference.
- the pH was adjusted with hydrochloric acid or NaOH. All were red when mixed. The color change was observed by leaving it at 50 ° C. for 3 days or more. It was found that a white solid could be made even if the pH was changed after mixing. A white solid could not be formed at a pH of 4 or higher.
- Example 23 Experiment in which raw materials were changed Hydrochloric acid was added to an aqueous solution of PQQ disodium salt, and the resulting PQQ-free material obtained by precipitation at pH 1 was added with water to give 3 g / L of an aqueous solution of 500 ⁇ L of PQQ-free material and calcium carbonate 1 g / liter. 750 ⁇ L of an aqueous solution of L was mixed and left at 70 ° C. overnight (pH 3.1). A white PQQ calcium compound was formed.
- Examples 24-28 Release of PQQ 10 mg of the white PQQ calcium salt prepared in Example 15 was added to 2 ml of each solvent shown in Table 4. After standing at 40 ° C. for 5 hours, the solid content was removed by centrifugation, and PQQ was analyzed by high performance liquid chromatography. It was found that the white PQQ calcium salt liberates calcium ions into a red solution in an environment with a lot of DMSO and phosphate ions. Further, it was found that artificial gastric juice hardly releases calcium ions, and neutral phosphate solution easily releases calcium ions. This indicates that the calcium salt of PQQ is a solid that is difficult to react in the stomach, but releases calcium ions when entering the intestine where it is easily absorbed. Furthermore, it was found that the acetate buffer had a small effect of removing the added water from the solid white PQQ calcium salt, and the added water was removed only from the dissolved part.
- Example 29 The following samples were subjected to structural analysis by NMR and XPS.
- 1 PQQ free body (red PQQ solid precipitated by adding hydrochloric acid to PQQ disodium salt aqueous solution and pH 1)
- 2 PQQ disodium salt (Comparative Example 2)
- 3 Red PQQ calcium compound (Example 17)
- 4 White PQQ calcium compound (Example 14)
- Solid NMR Measurement FIG. 4 shows the 1 H-solid NMR (wPMLG3) spectrum result.
- each signal was assigned from the chemical shift value. Although only 5 signals can be confirmed for 6 protons, since there are 3 COOHs from the structure of PQQ, it was estimated that 8-9 ppm signals were 2 COOH signals.
- FIG. 5 shows a 13 C-solid state NMR (CPMAS) spectrum (6 mm probe, 9 kHz).
- CPMAS 13 C-solid state NMR
- X-ray photoelectron spectroscopy (XPS) measurement In order to confirm the change of the functional group, XPS measurement was performed using ESCA3400 (manufactured by Shimadzu Corporation). The white PQQCa salt was placed in a high vacuum in the apparatus and was taken out after a lapse of a certain time. As a result, the color changed to red (red lighter than the red PQQCa salt). This was estimated from the CHNO analysis result described later because the water that had adhered adhered to the vacuum. Therefore, the XPS analysis result of the white PQQCa salt is considered to be the result after the color change, and is distinguished by * mark.
- Fig. 6 shows the measurement result of C1s.
- the peak top on the low energy side of C1s was adjusted to 285 eV.
- the C1s of the PQQ free body, red PQQCa salt, and white PQQCa salt were compared, the COO-derived peak was confirmed in the vicinity of 288 to 289 eV, but the PQQ-Ca red and PQQ-Ca white had a depression near 287 eV. It was considered that the peak derived from C ⁇ O decreased.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
加えて、PQQは反応性が高いことから、食品等と接触する場所では固体であり、吸収が行われる腸では溶液となるような形態が望ましい。
(1)ピロロキノリンキノンイオンとカルシウムイオンとのモル比が1:0.5~1.5である、ピロロキノリンキノンのカルシウム塩。
(2)ピロロキノリンキノンまたはそのアルカリ金属塩とカルシウムイオン源とを溶液中で混合して得られた混合物から析出させて得られる、(1)に記載のピロロキノリンキノンのカルシウム塩。
(3)カルシウムイオン源が、炭酸カルシウム、塩化カルシウム、および水酸化カルシウムからなる群から選択される、(2)に記載のピロロキノリンキノンのカルシウム塩。
(4)白色である、(1)~(3)のいずれかに記載のピロロキノリンキノンのカルシウム塩
(5)(1)~(4)のいずれかに記載のピロロキノリンキノンのカルシウム塩の結晶。
(6)粉末X線回折でCu Kα放射線を用いた2θのピークとして7.7°、10.6°、19.1°、26.4°、38.6°(いずれも±0.4°)を示す、(6)に記載のピロロキノリンキノンカルシウム塩の結晶。
(7)粉末X線回折でCu Kα放射線を用いた2θのピークとして9.8°、15.3°、17.1°、19.7°、26.3°、28.3°(いずれも±0.4°)を示す、(5)に記載のピロロキノリンキノンカルシウム塩の結晶。
(8)粉末X線回折でCu Kα放射線を用いた2θのピークとして8.8°、17.5°、25.4°、28.1°、30.5°、33.9°(いずれも±0.4°)を示す、(5)に記載のピロロキノリンキノンカルシウム塩の結晶。
(9)(1)~(4)のいずれかに記載のピロロキノリンキノンのカルシウム塩または(5)~(8)のいずれかに記載のピロロキノリンキノンカルシウム塩の結晶と、キレート性物質とを含んでなる、ピロロキノリンキノン含有組成物。
(10)キレート性物質が、リン酸、ピロリン酸、核酸、フィチン酸、酒石酸、コハク酸、クエン酸、EDTA、ヘキサメタリン酸およびポリリン酸からなる群から選択される1種以上である、(9)に記載の組成物。
(11)ピロロキノリンキノンまたはそのアルカリ金属塩とカルシウムイオン源とを溶液中で混合して得られた混合物から析出物を得ることを含んでなる、ピロロキノリンキノンのカルシウム塩の製造方法。
(12)混合物中に水が存在する、(11)に記載の製造方法。
(13)混合物のpHが4未満である、(11)または(12)に記載の製造方法。
(14)カルシウムイオン源が、炭酸カルシウム、塩化カルシウム、および水酸化カルシウムからなる群から選択される、(11)~(13)のいずれかに記載の製造方法。
(15)(11)~(14)のいずれかに記載の製造方法により製造される、ピロロキノリンキノンカルシウム塩。
(16)粉末X線回折でCu Kα放射線を用いた2θのピークとして7.7°、10.6°、19.1°、26.4°、38.6°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
(17)粉末X線回折でCu Kα放射線を用いた2θのピークとして9.8°、15.3°、17.1°、19.7°、26.3°、28.3°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
(18)粉末X線回折でCu Kα放射線を用いた2θのピークとして8.8°、17.5°、25.4°、28.1°、30.5°、33.9°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
(測定条件)
装置:株式会社RIGAKU製RINT2500
X線:Cu/管電圧40kV/管電流100mA
スキャンスピード:4.000°/min
サンプリング幅:0.020°
その他、モノクロメータが装着された一般的な粉末X線回折装置で観測することもできる。
PQQまたはそのアルカリ金属塩を水に溶解させる。溶解が完全に行われていなくても反応は進行することができる。pH調整のために酸、アルカリの溶液を加えて調整してもよい。この時のPQQまたはそのアルカリ金属塩の濃度は0.1から100g/Lであることが望ましく、より望ましくは1から20g/Lである。このときの温度は0から140℃で使用すれは良く、好ましくは20から90℃が特別な装置も要らず、使用しやすい。溶解度の面では高い温度が溶解しやすいため、50℃以上にするのが生産性を高める。ここに塩化カルシウムを加えることでカルシウム塩を析出させることができる。カルシウムは水溶液、粉末の形で添加することができる。混合する時間は特に制限がないが、5分から1週間ぐらいで行うことができる。スケールが小さい場合は短時間ですむが、大きな場合は長時間必要である。
(i)ピロロキノリンキノンまたはそのアルカリ金属塩の水溶液とカルシウムイオン源の水溶液とを混合すること;
(ii)工程(i)で得られた混合物から析出物を得ること;および
(iii)工程(ii)で得られた析出物を含む混合物をpH4未満で2時間以上置くこと。
あるいは、上記のCu Kα放射線を用いた2θのピークとして、少なくとも、8.8°、17.5°、25.4°、28.1°、30.5°、33.9°(いずれも±0.4°)を示すPQQカルシウムの結晶として得ることができる。当該PQQのカルシウム塩は白色である。
本発明の結晶は、単一の結晶であっても、これらの結晶の混合物であってもよい。
(i)pH2.5~4のピロロキノリンキノンまたはそのアルカリ金属塩の水溶液とカルシウムイオン源の水溶液とを混合すること;
(ii)工程(i)で得られた混合物から析出物を得ること
を含んでなる、ピロロキノリンキノンのカルシウム塩の製造方法および該製造方法により得られたピロロキノリンキノンのカルシウム塩(結晶)が提供される。このようにして得られたピロロキノリンキノンのカルシウム塩は、ピロロキノリンキノンとカルシウムイオンとの比が約1:1である。
(i)pH4.5~7のピロロキノリンキノンまたはそのアルカリ金属塩の水溶液とカルシウムイオン源の水溶液とを混合すること;
(ii)工程(i)で得られた混合物から析出物を得ること
を含んでなる、ピロロキノリンキノンのカルシウム塩の製造方法および該製造方法により得られたピロロキノリンキノンのカルシウム塩(結晶)が提供される。このようにして得られたピロロキノリンキノンのカルシウム塩は、ピロロキノリンキノンとカルシウムイオンとの比が約1:1.5である。
(i)pH2~7のピロロキノリンキノンまたはそのアルカリ金属塩の水溶液とカルシウムイオン源の水溶液とを混合すること;
(ii)工程(i)で得られた混合物から析出物を得ること;および
(iii)工程(ii)で得られた析出物を含む混合物をpH1.5~3.5で24時間以上置くこと
を含んでなる、ピロロキノリンキノンのカルシウム塩の製造方法および該製造方法により得られたピロロキノリンキノンのカルシウム塩(結晶)が提供される。このようにして得られたピロロキノリンキノンのカルシウム塩は白色である。
(i)pH2~7のピロロキノリンキノンまたはそのアルカリ金属塩の水溶液と、炭酸カルシウム、塩化カルシウム、および水酸化カルシウムからなる群から選択されるカルシウムイオン源の水溶液とを混合すること;
(ii)工程(i)で得られた混合物から析出物を得ること;および
(iii)工程(ii)で得られた析出物を含む混合物をpH1.5~3.5で24時間以上置くこと
を含んでなる、ピロロキノリンキノンのカルシウム塩の製造方法および該製造方法により得られたピロロキノリンキノンのカルシウム塩(結晶)が提供される。このようにして得られたピロロキノリンキノンのカルシウム塩は白色である。
〔1〕ピロロキノリンキノンイオンとカルシウムイオンの比が1:0.5から1.5であるピロロキノリンキノンのカルシウム塩。
〔2〕粉末X線回折でCu Kα放射線を用いた2θのピークとして7.7°、10.6°、19.1°、26.4°、38.6°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
〔3〕粉末X線回折でCu Kα放射線を用いた2θのピークとして9.8°、15.3、17.1、19.7°、26.3°、28.3°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
〔4〕ピロロキノリンキノンのカルシウム塩とキレート性物質を含む組成物。
〔5〕キレート性物質がリン酸、ピロリン酸、核酸、フィチン酸、酒石酸、コハク酸、クエン酸、EDTA、ヘキサメタリン酸及びポリリン酸からなる群より選ばれる1種以上であることを特徴とする〔4〕記載の組成物。
〔6〕ピロロキノリンキノンのアルカリ金属塩とカルシウム化合物を反応させることを特徴とするピロロキノリンキノンのカルシウム塩の製造方法。
(粉末X線回折)
装置:RIGAKU製RINT2500
X線:Cu/管電圧40kV/管電流100mA
発散スリット:2/3°
散乱スリット:2/3°
受光スリット:0.3mm
スキャンスピード:4.000°/min
サンプリング幅:0.02
(吸光度測定)
装置:HITACHI U-2000(日立)
(ICP分析)
装置:iCAP6500(Thermo Scientific)
(NMR測定)
装置:ECA-500(日本電子)
分析条件:
1H:wPMLG3
1H-13C:dipolar hetcor
回転数:10kHz
プローブ:固体3.2mm
試料管:窒化ケイ素製
(XPS分析)
装置:ESCA3400(島津製作所)
分析条件:
X線源:Mg Kα
出力:10kV 100W
P.E.:75
Resolution ナロー:high
(CHNO分析)
装置:EA1112(Thermo Finnigan)
分析条件:
燃焼温度:CHN:950℃;O:1060℃
カラムオーブン温度:CHN:65℃;O:75℃
検出器:TCD
検量線用標準物質:アンチピリン
特許第2692167号公報の実施例1に基づき、ハイホミクロビウム メチロボラム DSM1869を培養して得られた培養液を遠心分離して、菌体を除去し、PQQを含有する培養上澄液を得た。なお、この菌株はDSM(Deutsche Sammlung von Mikroorganismen (German Collection of Microorganisms and Cell Cultures)から入手できるものである。Sephadex G-10(ファルマシア製)カラムに、この培養上澄液を通過させてPQQを吸着させ、NaCl水溶液で溶出させて得られたpH7.5のPQQ水溶液をさらにNaClを60g/L濃度になるように加えて冷却し、固体を得た。得られた固体を水に溶かし高速液体クロマトグラフィーのUV吸収によるPQQ純度は99.0%以上であった。この固体をイオン交換水に溶解し、PQQ10g/Lを含む溶液を800g用意した。塩酸を加えてpHを3.5にした後、エタノールを200mL添加した。この時、赤色固体が析出した。室温下で5時間攪拌した後、5℃で24時間静置し、固体を析出させた。連続遠心分離で固体を回収し、50℃で減圧乾燥を行った。得られた固体の粉末X線回折スペクトルを測定した。得られた固体(PQQジナトリウム塩)には低角側でピークが見られる他は殆どピークが見られず、結晶性が低かった。
試験例1で得られたPQQジナトリウム塩1gを水100gに加え、NaOHでpH6.4に調整した。塩化カルシウム1gを水40mlに溶解した液を加え、一晩攪拌した後、析出した固体をろ過し、水、エタノールで洗った。これを減圧乾燥50℃で一晩行った。濃赤色結晶の重量1.18gを得た。含水量23%であった。ICP分析を使って分析した結果、PQQ1に対してCa1.5molの比で含有しており、Na含有量0でナトリウムは含まれていなかった。得られたカルシウム体の粉末X線回折の結果を図1に示す。7.7°、10.6°、19.1°、26.4°、38.6°にピークを有する結晶性PQQカルシウム塩であった。この固体は結晶性で水溶性の低い物質であった。
PQQジナトリウム塩3gを水800gに加え溶解した。この時のpHは3.5であった。塩化カルシウム6gを水100mlに溶解した液を加え、2日間攪拌後、析出した固体をろ過し、水、エタノールで洗った。これを減圧乾燥70℃で一晩行い赤色の固体3.29gを得た。含水量11%であった。ICP分析を使って分析した結果、PQQ1に対してCa1molの比で含有しており、Na含有量0でナトリウムは含まれていなかった。得られたカルシウム塩の粉末X線回折は図2に示す。9.8°、15.3、17.1、19.7°、26.3°、28.3°にピークを有する結晶性PQQカルシウム塩であった。この固体は結晶性で水溶性の低い物質であった。
PQQは培養動物細胞に対して増殖を増やす効果と高濃度にすると細胞の増殖を抑える効果がある。これを利用して細胞吸収がどのように変化するかを試験した。
チャイニーズハムスター卵巣細胞(CHO-DHFR-、大日本住友製薬社製)をα‐MEM+10%牛胎児血清の培地で5%CO2, 37℃で培養した。イワキ製96穴プレート使用し、1個の穴に6000個の細胞になるように100μlの培地とともに加え、一晩培養した。培養液を抜き、所定の試験濃度の培地を加えた。2日培養後、培地を入れ替え、Cell Counting Kit 8(同仁化学社製)を使用して1時間反応させ、450nmの吸光度を測定した。この時の吸光度は細胞数に比例する。
無添加と比較してPQQによる細胞数が最も多くなっている濃度(5%程度)を最適増殖濃度として記載する。また、全細胞数が無添加と比較して10%程度少なくなる添加量を増殖低下濃度として記載する。その結果を以下の表1に示す。
キレート性物質を添加することによる不溶性の塩の溶解性の変化を測定した。キレート性物質を実施例1、2で得られた結晶PQQカルシウム塩と混合し水1mlに加え、4時間室温で放置した後、遠心分離で不溶成分を除いた液を450nmでの吸収からPQQの溶解量を測定した。その結果を表2に示す。
実施例1と同様に実験を行った。ただし、PQQジナトリウム塩の水溶液はpH4.8にあわせた。回収量等は実施例1と変わりなく、粉末X線回折の分析結果も実施例1と同様の結晶構造を有していた。PQQ1に対してCa1.5molの比の塩であった。
実施例2と同様の操作を行った。ただし、PQQジナトリウム塩の水溶液はpH2.9にあわせた。回収量等は実施例2と同様で、粉末X線回折の分析結果は実施例2の結晶(PQQ:Ca=1:1の塩)とともに他の結晶構造も混合された結晶性物質であった。
ピロロキノリンキノンのカリウム塩0.54gを水300mlに溶かしてpHを6.6にした。塩化カルシウム1.4gを含む水溶液20mlと混合し、一晩攪拌した。ろ過した後、水、エタノールで洗浄後、減圧乾燥して0.42gの固体を得た。得られた物質の粉末X線回折は実施例1と同様のピークを与え、PQQ1に対してCa1.5molの比のカルシウム塩が製造できた。
試験例1で得られたPQQジナトリウム塩を水に溶かし、2g/Lの水溶液を作製した。この水溶液400mlに2Nの塩酸を2ml加えた。塩化カルシウム(2g/L)の水溶液170mlと温度10℃で混合した。混合時のpHは2.3であった。30分間10℃にしたのち、40℃にして3日間攪拌した。これをろ過し、50mlの水で洗浄し白色固体を得た。減圧乾燥を一晩行い、0.76gの固体を得た。粉末X線回析結果を図3に示す。8.8°、17.5°、25.4°、28.1°、30.5°、33.9°にピークを示す結晶性の白色物質であった。
試験例1で得られたPQQジナトリウム塩を水に溶かし、2g/Lの水溶液を作製した。この水溶液400mlに2Nの塩酸を2ml加えた。塩化カルシウム(2g/L)の水溶液170mlと温度10℃で混合した。混合時のpHは2.3であった。10℃で3日間おいた。これをろ過し、50mlの水で洗浄し白色固体を得た。減圧乾燥を一晩行い、0.78gの固体を得た。粉末X線回析結果は実施例14と同じであった。
試験例1で得られたPQQジナトリウム塩を水に溶かし、2g/Lの水溶液を作製した。この水溶液250mlに2Nの塩酸を0.6ml加えた。塩化カルシウム(2g/L)の水溶液120mlを室温(約20℃)で混合した。混合時のpHは2.6であった。40℃で6日攪拌した。これをろ過し、10mlのエタノールで洗浄し白色固体を得た。減圧乾燥を一晩行い、0.50gの固体を得た。粉末X線回析結果は実施例14と同じであった。
10℃で混合後、30分でろ過する以外は実施例15と同様に実験を行った。その結果、赤色固体を得た。減圧乾燥を一晩行い、0.79gの赤色固体を得た。
試験例1で得られたPQQジナトリウム塩を水に溶かし、2g/Lの水溶液を作製した。この水溶液250mlに酢酸を4.19g加えた。塩化カルシウム(2g/L)の水溶液120mlと室温で混合した。混合時のpHは2.8であった。40℃で6日攪拌し、これをろ過し、10mlのエタノールで洗浄し白色固体を得た。減圧乾燥を一晩行い、0.51gの白色固体を得た。
試験例1で得られたPQQジナトリウム塩を水に溶かし、2g/Lの水溶液を作製した。この水溶液400mlに2Nの塩酸を2ml加えた。塩化カルシウム(2g/L)の水溶液170mlと室温で混合した。混合時のpHは2.3であった。5分後70℃にして1日間放置した。赤色と白色の固体が生じていた。これを50mlの遠沈管に分けて入れ、遠心分離機HITACHI himac CF7D2に入れ、2000回転30分おこなった。容器の底に赤色が下、白色が上の層になって沈降していた。比重差で白色固体と赤色固体とを分離することができた。
PQQジナトリウム塩水溶液(2g/L)と塩化カルシウム水溶液(2g/L)を2:1ので混合した。pHは塩酸またはNaOHで調整した。混合時は全て赤色であった。50℃で3日以上放置して色の変化を観察した。
PQQジナトリウム塩水溶液に塩酸を加え、pH1で析出させて得られたPQQフリー体に水を加え3g/LとしたPQQフリー体の水溶液500μLと炭酸カルシウム1g/Lの水溶液750μLを混合して70℃で一晩放置した(pH3.1)。白色PQQカルシウム化合物が生成した。
実施例15で製造した白色のPQQカルシウム塩10mgを2mlの表4に示す各溶媒に加えた。40℃で5時間放置した後、遠心分離で固体分を除き、高速液体クロマトグラフィーでPQQを分析した。
以下の各試料について、NMR及びXPSによる構造解析を行った。
1:PQQフリー体(PQQジナトリウム塩水溶液に塩酸を加えpH1で析出した赤色PQQ固体)
2:PQQジナトリウム塩(比較例2)
3:赤色PQQカルシウム化合物(実施例17)
4 白色PQQカルシウム化合物(実施例14)
固体NMR測定
図4に1H-固体NMR(wPMLG3)スペクトル結果を示した。PQQフリー体についてはケミカルシフト値から各シグナルを帰属した。6個のプロトンに対し、5本のシグナルしか確認できないが、PQQの構造から3個のCOOHがあるため、8~9ppmのシグナルが2個分のCOOHシグナルであると推定した。一方、PQQ-Na赤、PQQ-Ca赤、PQQ-Ca白では5~6ppmに五員環H(a)のシグナルを確認した。また、各試料、5ppm以下(高磁場側)にNH由来と推定されるシグナルを確認したが、PQQ-Ca白は2本のシグナルが重なった形状であり、他の試料には無いシグナルを確認した。
官能基の変化を確認するため、ESCA3400(島津製作所社製)を用いてXPS測定を行った。白色PQQCa塩については装置内で高真空下に置き、一定時間経過後に取り出したところ、色が赤く(赤色PQQCa塩よりは薄い赤色)変化していた。これは後述するCHNO分析結果から、付着していた水が真空化で飛んだためと推定した。従って白色PQQCa塩のXPS分析結果は色の変化後の結果であると考えられ、*印で区別した。
モル比(N=1として)でPQQ-Ca赤とPQQ-Ca白を比較するとHとOに差が有り、差分の組成はH2O(またはH3O)に相当した。また真空引き前後(PQQ-Ca白とPQQ-Ca白*)で比較してもHとOに差が有り、差分の組成はH2Oに相当した。
Claims (18)
- ピロロキノリンキノンイオンとカルシウムイオンとのモル比が1:0.5~1.5である、ピロロキノリンキノンのカルシウム塩。
- ピロロキノリンキノンまたはそのアルカリ金属塩とカルシウムイオン源とを溶液中で混合して得られた混合物から析出させて得られる、請求項1に記載のピロロキノリンキノンのカルシウム塩。
- カルシウムイオン源が、炭酸カルシウム、塩化カルシウム、および水酸化カルシウムからなる群から選択される、請求項2に記載のピロロキノリンキノンのカルシウム塩。
- 白色である、請求項1~3のいずれか一項に記載のピロロキノリンキノンのカルシウム塩。
- 請求項1~4のいずれか一項に記載のピロロキノリンキノンのカルシウム塩の結晶。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして7.7°、10.6°、19.1°、26.4°、38.6°(いずれも±0.4°)を示す、請求項5に記載のピロロキノリンキノンカルシウム塩の結晶。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして9.8°、15.3°、17.1°、19.7°、26.3°、28.3°(いずれも±0.4°)を示す、請求項5に記載のピロロキノリンキノンカルシウム塩の結晶。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして8.8°、17.5°、25.4°、28.1°、30.5°、33.9°(いずれも±0.4°)を示す、請求項5に記載のピロロキノリンキノンカルシウム塩の結晶。
- 請求項1~4のいずれか一項に記載のピロロキノリンキノンのカルシウム塩または請求項5~8のいずれか一項に記載のピロロキノリンキノンカルシウム塩の結晶と、キレート性物質とを含んでなる、ピロロキノリンキノン含有組成物。
- キレート性物質が、リン酸、ピロリン酸、核酸、フィチン酸、酒石酸、コハク酸、クエン酸、EDTA、ヘキサメタリン酸およびポリリン酸からなる群から選択される1種以上である、請求項9に記載の組成物。
- ピロロキノリンキノンまたはそのアルカリ金属塩とカルシウムイオン源とを溶液中で混合して得られた混合物から析出物を得ることを含んでなる、ピロロキノリンキノンのカルシウム塩の製造方法。
- 混合物中に水が存在する、請求項11に記載の製造方法。
- 混合物のpHが4未満である、請求項11または12に記載の製造方法。
- カルシウムイオン源が、炭酸カルシウム、塩化カルシウム、および水酸化カルシウムからなる群から選択される、請求項11~13のいずれか一項に記載の製造方法。
- 請求項11~14のいずれか一項に記載の製造方法により製造される、ピロロキノリンキノンカルシウム塩。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして7.7°、10.6°、19.1°、26.4°、38.6°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして9.8°、15.3°、17.1°、19.7°、26.3°、28.3°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして8.8°、17.5°、25.4°、28.1°、30.5°、33.9°(いずれも±0.4°)を示すピロロキノリンキノンカルシウム塩の結晶。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/825,228 US8969563B2 (en) | 2010-09-22 | 2011-09-22 | Calcium salt of pyrroloquinoline quinone |
CN201180045652.1A CN103119044B (zh) | 2010-09-22 | 2011-09-22 | 吡咯并喹啉醌的钙盐 |
JP2012535081A JP5842819B2 (ja) | 2010-09-22 | 2011-09-22 | ピロロキノリンキノンのカルシウム塩 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010211883 | 2010-09-22 | ||
JP2010-211883 | 2010-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012039474A1 true WO2012039474A1 (ja) | 2012-03-29 |
Family
ID=45873957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/071697 WO2012039474A1 (ja) | 2010-09-22 | 2011-09-22 | ピロロキノリンキノンのカルシウム塩 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8969563B2 (ja) |
JP (1) | JP5842819B2 (ja) |
CN (1) | CN103119044B (ja) |
WO (1) | WO2012039474A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013103913A (ja) * | 2011-11-15 | 2013-05-30 | Nisshin Pharma Inc | 難着色性ピロロキノリンキノン類含有製剤 |
JP2013237644A (ja) * | 2012-05-16 | 2013-11-28 | Mitsubishi Gas Chemical Co Inc | 細胞活性化炭酸水 |
WO2014027669A1 (ja) * | 2012-08-17 | 2014-02-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
JP2017031126A (ja) * | 2015-08-06 | 2017-02-09 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン結晶の製造方法 |
US11120437B2 (en) | 2016-02-23 | 2021-09-14 | nChain Holdings Limited | Registry and automated management method for blockchain-enforced smart contracts |
US11126976B2 (en) | 2016-02-23 | 2021-09-21 | nChain Holdings Limited | Method and system for efficient transfer of cryptocurrency associated with a payroll on a blockchain that leads to an automated payroll method and system based on smart contracts |
US11182782B2 (en) | 2016-02-23 | 2021-11-23 | nChain Holdings Limited | Tokenisation method and system for implementing exchanges on a blockchain |
US11194898B2 (en) | 2016-02-23 | 2021-12-07 | nChain Holdings Limited | Agent-based turing complete transactions integrating feedback within a blockchain system |
US11308486B2 (en) | 2016-02-23 | 2022-04-19 | nChain Holdings Limited | Method and system for the secure transfer of entities on a blockchain |
US11349645B2 (en) | 2016-02-23 | 2022-05-31 | Nchain Holdings Ltd. | Determining a common secret for the secure exchange of information and hierarchical, deterministic cryptographic keys |
US11356280B2 (en) | 2016-02-23 | 2022-06-07 | Nchain Holdings Ltd | Personal device security using cryptocurrency wallets |
US11373152B2 (en) | 2016-02-23 | 2022-06-28 | nChain Holdings Limited | Universal tokenisation system for blockchain-based cryptocurrencies |
US11410145B2 (en) | 2016-02-23 | 2022-08-09 | nChain Holdings Limited | Blockchain-implemented method for control and distribution of digital content |
US11455378B2 (en) | 2016-02-23 | 2022-09-27 | nChain Holdings Limited | Method and system for securing computer software using a distributed hash table and a blockchain |
US11606219B2 (en) | 2016-02-23 | 2023-03-14 | Nchain Licensing Ag | System and method for controlling asset-related actions via a block chain |
US11621833B2 (en) | 2016-02-23 | 2023-04-04 | Nchain Licensing Ag | Secure multiparty loss resistant storage and transfer of cryptographic keys for blockchain based systems in conjunction with a wallet management system |
US11625694B2 (en) | 2016-02-23 | 2023-04-11 | Nchain Licensing Ag | Blockchain-based exchange with tokenisation |
US11727501B2 (en) | 2016-02-23 | 2023-08-15 | Nchain Licensing Ag | Cryptographic method and system for secure extraction of data from a blockchain |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10364244B2 (en) | 2015-09-25 | 2019-07-30 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Crystal form of pyrroloquinoline quinone sodium salt and preparation method and use thereof |
JP7412682B2 (ja) * | 2018-08-30 | 2024-01-15 | 三菱瓦斯化学株式会社 | 光劣化抑制剤、それを含む飲料、及び光劣化抑制方法 |
CN113424950A (zh) * | 2021-07-09 | 2021-09-24 | 长沙宾和朋食品有限公司 | 一种添加吡咯并喹啉醌的槟榔卤水及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62246575A (ja) * | 1986-04-17 | 1987-10-27 | Mitsubishi Gas Chem Co Inc | ピロロキノリンキノンの精製方法 |
JPH0253477A (ja) * | 1988-08-18 | 1990-02-22 | Nakano Vinegar Co Ltd | 酢酸発酵促進用組成物およびそれを用いる食酢の製造法 |
JPH03112912A (ja) * | 1989-09-27 | 1991-05-14 | Sanko Seibutsu Kagaku Kenkyusho:Kk | 化粧料組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3475969B2 (ja) | 1993-08-27 | 2003-12-10 | 大日本インキ化学工業株式会社 | 共重合体樹脂エマルジョン、その製造方法及び防湿加工用組成物 |
JP5392089B2 (ja) * | 2007-11-14 | 2014-01-22 | 三菱瓦斯化学株式会社 | 皮膚の乾癬予防または改善剤 |
-
2011
- 2011-09-22 WO PCT/JP2011/071697 patent/WO2012039474A1/ja active Application Filing
- 2011-09-22 JP JP2012535081A patent/JP5842819B2/ja active Active
- 2011-09-22 CN CN201180045652.1A patent/CN103119044B/zh active Active
- 2011-09-22 US US13/825,228 patent/US8969563B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62246575A (ja) * | 1986-04-17 | 1987-10-27 | Mitsubishi Gas Chem Co Inc | ピロロキノリンキノンの精製方法 |
JPH0253477A (ja) * | 1988-08-18 | 1990-02-22 | Nakano Vinegar Co Ltd | 酢酸発酵促進用組成物およびそれを用いる食酢の製造法 |
JPH03112912A (ja) * | 1989-09-27 | 1991-05-14 | Sanko Seibutsu Kagaku Kenkyusho:Kk | 化粧料組成物 |
Non-Patent Citations (1)
Title |
---|
BERGE, S.M. ET AL.: "Pharmaceutical salts", J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013103913A (ja) * | 2011-11-15 | 2013-05-30 | Nisshin Pharma Inc | 難着色性ピロロキノリンキノン類含有製剤 |
JP2013237644A (ja) * | 2012-05-16 | 2013-11-28 | Mitsubishi Gas Chemical Co Inc | 細胞活性化炭酸水 |
WO2014027669A1 (ja) * | 2012-08-17 | 2014-02-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
US9394298B2 (en) | 2012-08-17 | 2016-07-19 | Mitsubishi Gas Chemical Company, Inc. | Pyrroloquinoline quinone tetraalkali salt and crystal thereof, methods for producing these, and composition |
JPWO2014027669A1 (ja) * | 2012-08-17 | 2016-07-28 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
JP2017031126A (ja) * | 2015-08-06 | 2017-02-09 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン結晶の製造方法 |
US11120437B2 (en) | 2016-02-23 | 2021-09-14 | nChain Holdings Limited | Registry and automated management method for blockchain-enforced smart contracts |
US11126976B2 (en) | 2016-02-23 | 2021-09-21 | nChain Holdings Limited | Method and system for efficient transfer of cryptocurrency associated with a payroll on a blockchain that leads to an automated payroll method and system based on smart contracts |
US11182782B2 (en) | 2016-02-23 | 2021-11-23 | nChain Holdings Limited | Tokenisation method and system for implementing exchanges on a blockchain |
US11194898B2 (en) | 2016-02-23 | 2021-12-07 | nChain Holdings Limited | Agent-based turing complete transactions integrating feedback within a blockchain system |
US11308486B2 (en) | 2016-02-23 | 2022-04-19 | nChain Holdings Limited | Method and system for the secure transfer of entities on a blockchain |
US11347838B2 (en) | 2016-02-23 | 2022-05-31 | Nchain Holdings Ltd. | Blockchain implemented counting system and method for use in secure voting and distribution |
US11349645B2 (en) | 2016-02-23 | 2022-05-31 | Nchain Holdings Ltd. | Determining a common secret for the secure exchange of information and hierarchical, deterministic cryptographic keys |
US11356280B2 (en) | 2016-02-23 | 2022-06-07 | Nchain Holdings Ltd | Personal device security using cryptocurrency wallets |
US11373152B2 (en) | 2016-02-23 | 2022-06-28 | nChain Holdings Limited | Universal tokenisation system for blockchain-based cryptocurrencies |
US11410145B2 (en) | 2016-02-23 | 2022-08-09 | nChain Holdings Limited | Blockchain-implemented method for control and distribution of digital content |
US11455378B2 (en) | 2016-02-23 | 2022-09-27 | nChain Holdings Limited | Method and system for securing computer software using a distributed hash table and a blockchain |
US11606219B2 (en) | 2016-02-23 | 2023-03-14 | Nchain Licensing Ag | System and method for controlling asset-related actions via a block chain |
US11621833B2 (en) | 2016-02-23 | 2023-04-04 | Nchain Licensing Ag | Secure multiparty loss resistant storage and transfer of cryptographic keys for blockchain based systems in conjunction with a wallet management system |
US11625694B2 (en) | 2016-02-23 | 2023-04-11 | Nchain Licensing Ag | Blockchain-based exchange with tokenisation |
US11727501B2 (en) | 2016-02-23 | 2023-08-15 | Nchain Licensing Ag | Cryptographic method and system for secure extraction of data from a blockchain |
US11755718B2 (en) | 2016-02-23 | 2023-09-12 | Nchain Licensing Ag | Blockchain implemented counting system and method for use in secure voting and distribution |
US11936774B2 (en) | 2016-02-23 | 2024-03-19 | Nchain Licensing Ag | Determining a common secret for the secure exchange of information and hierarchical, deterministic cryptographic keys |
US11972422B2 (en) | 2016-02-23 | 2024-04-30 | Nchain Licensing Ag | Registry and automated management method for blockchain-enforced smart contracts |
Also Published As
Publication number | Publication date |
---|---|
JP5842819B2 (ja) | 2016-01-13 |
CN103119044A (zh) | 2013-05-22 |
JPWO2012039474A1 (ja) | 2014-02-03 |
CN103119044B (zh) | 2017-02-08 |
US20130225632A1 (en) | 2013-08-29 |
US8969563B2 (en) | 2015-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5842819B2 (ja) | ピロロキノリンキノンのカルシウム塩 | |
US9321770B2 (en) | Crystals of pyrroloquinolinequinone sodium salts | |
US8946423B2 (en) | Highly soluble salt of pyrroloquinoline quinone and method for producing the same | |
JP6160621B2 (ja) | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 | |
CN101143863B (zh) | 5-甲基四氢叶酸的拆分及其成盐方法 | |
EP2497769A1 (en) | Pyrroloquinoline quinone in free form | |
JP2023099033A (ja) | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 | |
JP6166736B2 (ja) | (6s)−5−メチルテトラヒドロ葉酸塩の結晶形及びそれを製造する方法 | |
JP5636671B2 (ja) | ピロロキノリンキノンLi塩の製造方法 | |
US10100055B2 (en) | Imidazopyrroloquinoline salt, method for producing the same, medicament, cosmetic, and food | |
TW202024013A (zh) | 用於製備α-酮戊二酸鈣之方法 | |
JP6395101B2 (ja) | イミダゾピロロキノリン塩 | |
JP2017031126A (ja) | ピロロキノリンキノン結晶の製造方法 | |
US20180009803A1 (en) | High-solubility acetone-added pyrroloquinoline quinone salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180045652.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11826919 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012535081 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13825228 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11826919 Country of ref document: EP Kind code of ref document: A1 |